Form 4: Mereo BioPharma CEO Sells Shares to Cover Tax Obligations

Mereo BioPharma Group plc CEO, Denise Scots-Knight, sold American Depositary Shares (ADSs) to cover tax withholding obligations related to vested performance-based restricted stock units.

Summary

• Denise Scots-Knight, CEO of Mereo BioPharma Group plc, reported the sale of American Depositary Shares (ADSs) on June 25 and June 26, 2024.
• The sales were executed to cover tax withholding obligations associated with the vesting of performance-based restricted stock units under the company's 2019 Employee Incentive Plan.
• On June 25, 2024, 40,712 ADSs were sold at a weighted average price of $3.6939, with prices ranging from $3.60 to $3.805.
• On June 26, 2024, 92,273 ADSs were sold at a weighted average price of $3.3932, with prices ranging from $3.28 to $3.51.
• Following these transactions, Scots-Knight beneficially owns 709,518 ADSs, which includes 1,200 ADSs jointly owned with her spouse, as well as 4 ordinary shares.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, which is neither particularly positive nor negative.

Positives

• The 'sell to cover' transaction ensures that tax obligations are met without requiring discretionary trades by the Reporting Person.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives.

Stakeholder Impact

• The sale of shares may have a minor impact on shareholders due to the increased supply of shares in the market, but it is primarily driven by tax obligations.

Key Dates